The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite ...

The stock of Caris Life Sciences shined in its Nasdaq debut on Wednesday, pricing its heavily-subscribed initial public ...

Caris Life Sciences raised $494.1 million in its Nasdaq initial public offering, the cancer diagnostic firm said on Tuesday, ...

With the successful IPO of Caris Life Sciences makes its founder David Dean Halbert worth an estimated $3.3 billion.

Caris Life Sciences shares rose on their first day of trading in their debut on Nasdaq. The biotechnology company started trading at $27 each on Wednesday afternoon, a day after the company's IPO was ...

Caris Life Sciences bumped up the pricing of its IPO to raise more than $494.1 million in its Nasdaq debut—well over the ...

Cancer-testing company raises $494 million in initial public offering.

Caris Life Sciences shares ended trading at $28 per share on Wednesday, marking a 33% increase from its initial public offering (IPO) price of $21 per share.

Recent health news highlights include global bird flu restrictions impacting Brazilian chicken exports, advancements in ...

The biotech firm filed its IPO paperwork May 23 in a bid to boost its finances, noting there was "substantial doubt" about ...

Caris Life Sciences' shares jumped nearly 29% in their Nasdaq debut on Wednesday, fetching the cancer diagnostic firm a ...

Shares of Caris Life Sciences soared in their public debut Wednesday, as investors bought into the company’s business of ...